- call +1-201-465-4211
- email sales@mrinsights.biz
Multiple sclerosis (MS) is a nervous system disease which affects spinal cord and the brain. MS damages the myelin sheath. Myelin sheath is a term which exemplifies that material which surrounds and protects human nerve cells. This damage blocks messages between brain and the body and leads to the symptoms of MS. Some of the major symptoms of MS include thinking and memory problems, visual disturbances, problem in coordination and balancing of the body and muscle weakness.
Scope of the Report:
This report studies the Multiple Sclerosis Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Multiple Sclerosis Drugs market by product type and applications/end industries.
MS affects women more than men. The disease often occurs between age group of 20-40. MS is mainly divided into four types. They are relapsing-remitting MS, progressive-relapsing MS, secondary-progressive MS and primary-progressive MS. Relapsing-remitting MS is the most common form of the disease. It accounts about 85% of the total MS cases. Secondary-progressive is associated with the initial period of relapsing-remitting disease. Approximately, 50% of people suffering with relapsing remitting MS would develop this form of the disease. Progressive-relapsing MS is rare and about 5% of the total MS cases. Primary-progressive MS accounts 10% of the total MS cases.
In terms of geographic, North America dominates the global MS drugs market. The U.S. represents the largest market for MS drugs followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of MS drugs market. However, Asia is expected to show high growth rates in the next five years in global MS drugs market. This is due to many companies constructing their manufacturing and research facilities in the region. Developing regions have advantage over the developed regions due to low wages, availability of a large talent pool, less stringent environment and health and safety regulations. Japan, China and India are expected to be the fastest growing MS drugs markets in Asia.
The global Multiple Sclerosis Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Multiple Sclerosis Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
GlaxoSmithKline
Novartis
Merck
Sanofi
Pfizer
Bayer
Teva Pharmaceutical
Abbvie
Biogen Idec
AB Science
Opexa
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Oral Drugs
Parenteral Drugs
Market Segment by Applications, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Multiple Sclerosis Drugs Market Overview
1.1 Product Overview and Scope of Multiple Sclerosis Drugs
1.2 Classification of Multiple Sclerosis Drugs by Types
1.2.1 Global Multiple Sclerosis Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global Multiple Sclerosis Drugs Revenue Market Share by Types in 2017
1.2.3 Oral Drugs
1.2.4 Parenteral Drugs
1.3 Global Multiple Sclerosis Drugs Market by Application
1.3.1 Global Multiple Sclerosis Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Multiple Sclerosis Drugs Market by Regions
1.4.1 Global Multiple Sclerosis Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Multiple Sclerosis Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Multiple Sclerosis Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Multiple Sclerosis Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Multiple Sclerosis Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Multiple Sclerosis Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of Multiple Sclerosis Drugs (2013-2023)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Multiple Sclerosis Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Multiple Sclerosis Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 Merck
2.3.1 Business Overview
2.3.2 Multiple Sclerosis Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Sanofi
2.4.1 Business Overview
2.4.2 Multiple Sclerosis Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sanofi Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Multiple Sclerosis Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer
2.6.1 Business Overview
2.6.2 Multiple Sclerosis Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Bayer Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 Teva Pharmaceutical
2.7.1 Business Overview
2.7.2 Multiple Sclerosis Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Teva Pharmaceutical Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.8 Abbvie
2.8.1 Business Overview
2.8.2 Multiple Sclerosis Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Abbvie Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.9 Biogen Idec
2.9.1 Business Overview
2.9.2 Multiple Sclerosis Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Biogen Idec Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.10 AB Science
2.10.1 Business Overview
2.10.2 Multiple Sclerosis Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 AB Science Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.11 Opexa
2.11.1 Business Overview
2.11.2 Multiple Sclerosis Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Opexa Multiple Sclerosis Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global Multiple Sclerosis Drugs Market Competition, by Players
3.1 Global Multiple Sclerosis Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Multiple Sclerosis Drugs Players Market Share
3.2.2 Top 10 Multiple Sclerosis Drugs Players Market Share
3.3 Market Competition Trend
4 Global Multiple Sclerosis Drugs Market Size by Regions
4.1 Global Multiple Sclerosis Drugs Revenue and Market Share by Regions
4.2 North America Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
4.5 South America Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
5 North America Multiple Sclerosis Drugs Revenue by Countries
5.1 North America Multiple Sclerosis Drugs Revenue by Countries (2013-2018)
5.2 USA Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
6 Europe Multiple Sclerosis Drugs Revenue by Countries
6.1 Europe Multiple Sclerosis Drugs Revenue by Countries (2013-2018)
6.2 Germany Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
6.3 UK Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
6.4 France Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Multiple Sclerosis Drugs Revenue by Countries
7.1 Asia-Pacific Multiple Sclerosis Drugs Revenue by Countries (2013-2018)
7.2 China Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
7.5 India Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
8 South America Multiple Sclerosis Drugs Revenue by Countries
8.1 South America Multiple Sclerosis Drugs Revenue by Countries (2013-2018)
8.2 Brazil Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Multiple Sclerosis Drugs by Countries
9.1 Middle East and Africa Multiple Sclerosis Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa Multiple Sclerosis Drugs Revenue and Growth Rate (2013-2018)
10 Global Multiple Sclerosis Drugs Market Segment by Type
10.1 Global Multiple Sclerosis Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global Multiple Sclerosis Drugs Market Forecast by Type (2018-2023)
10.3 Oral Drugs Revenue Growth Rate (2013-2023)
10.4 Parenteral Drugs Revenue Growth Rate (2013-2023)
11 Global Multiple Sclerosis Drugs Market Segment by Application
11.1 Global Multiple Sclerosis Drugs Revenue Market Share by Application (2013-2018)
11.2 Multiple Sclerosis Drugs Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacies Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Online Pharmacies Revenue Growth (2013-2018)
12 Global Multiple Sclerosis Drugs Market Size Forecast (2018-2023)
12.1 Global Multiple Sclerosis Drugs Market Size Forecast (2018-2023)
12.2 Global Multiple Sclerosis Drugs Market Forecast by Regions (2018-2023)
12.3 North America Multiple Sclerosis Drugs Revenue Market Forecast (2018-2023)
12.4 Europe Multiple Sclerosis Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Multiple Sclerosis Drugs Revenue Market Forecast (2018-2023)
12.6 South America Multiple Sclerosis Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Multiple Sclerosis Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Multiple Sclerosis Drugs Picture
Table Product Specifications of Multiple Sclerosis Drugs
Table Global Multiple Sclerosis Drugs and Revenue (Million USD) Market Spli
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
